Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03252015 · ClinicalTrials.gov registry record · Phase 1
A Study of Multiple Doses of Lasmiditan in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT03252015 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 70 participants.
The verdict
NCT03252015, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this study is to look at how much lasmiditan, study drug, gets into the blood stream and how long it takes the body to get rid of it. When drugs are taken together, one or all of the drugs used in combination may be affected. This study will also evaluate the concentrations in the blood of a probe drug cocktail taken alone and in combination with lasmiditan. Information about any side effects that may occur will also be collected. The study has two parts. Participants will only enroll in one part. This study will last about 25 days for group 1 and 22 days for group 2, not including screening. Screening is required within 28 days prior to the start of the study. This study is for research purposes only and is not intended to treat any medical condition.
Interventions
- DRUG Placebo
- DRUG Lasmiditan
- DRUG Probe Drug Cocktail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2017-08-15 |
| Est. Completion | 2018-01-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03252015
The ClinicalTrials.gov registry entry for NCT03252015 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03252015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03252015 about?
NCT03252015 is a clinical study titled "A Study of Multiple Doses of Lasmiditan in Healthy Participants". The purpose of this study is to look at how much lasmiditan, study drug, gets into the blood stream and how long it takes the body to get rid of it. When drugs are taken together, one or all of the drugs used in combination may be affected. This study will also evaluate the concentrations in the bl...
What is the current status of trial NCT03252015?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2017-08-15. Estimated completion is 2018-01-02.
What interventions are being tested in trial NCT03252015?
The interventions under investigation include: Placebo (DRUG), Lasmiditan (DRUG), Probe Drug Cocktail (DRUG).
Who is sponsoring clinical trial NCT03252015?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.